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ABSTRACT The structure of a 36-amino-acid-long N-terminal fragment of human phospholamban phosphorylated at
Ser-16 and Thr-17 and Cys-363Ser mutated was determined from nuclear magnetic resonance data in aqueous solution
containing 30% trifluoroethanol. The peptide assumes a conformation characterized by two -helices connected by an
irregular strand, which comprises the amino acids from Arg-13 to Pro-21. The proline is in a trans conformation. The two
phosphate groups on Ser-16 and Thr-17 are shown to interact preferably with the side chains of Arg-14 and Arg-13,
respectively. The helix comprising amino acids 22 to 35 is well determined (the rmsd for the backbone atoms, calculated for
a family of 24 nuclear magnetic resonance structures is 0.69  0.28 Å). The structures of phosphorylated and unphosphor-
ylated phospholamban are compared, and the effect of the two phosphate groups on the relative spatial position of the two
helices is examined. The packing parameters  (interhelical angle) and d (minimal interhelical distance) are calculated: in the
case of the phosphorylated phospholamban,   100  35° and d  7.9  4.6 Å, whereas for the unphosphorylated peptide
the values are   80  20° and d  7.0  4.0 Å. We conclude that 1) the phosphorylation does not affect the structure of
the C terminus between residues 21 and 36 and 2) the phosphorylated phospholamban has more loose helical packing than
the nonphosphorylated.
INTRODUCTION
Phospholamban (PLB) is a small protein (52 amino acids)
that regulates the affinity of the cardiac sarcoplasmic retic-
ulum Ca2-ATPase (SERCA2a) for calcium. The role of
PLB in the regulation of the cardiac contraction has been
defined by gene transfer (Kadambi et al., 1996) and knock-
out (Luo et al., 1994) technology in the mouse. PLB is
present not only in cardiac myocytes but also in slow-twitch
and smooth muscle. Recently, evidence was given that PLB
is expressed also in aorta endothelial cells (Paul, 1998) in
which it could play a role in the tissue relaxation (Sutliff et
al., 1999).
PLB can be phosphorylated by both cAMP- (Karczewski
et al., 1987) and Ca2/calmodulin-dependent phosphokinases
(Iwasa et al., 1985). The phosphorylation/dephosphorylation of
phospholamban removes and restores, respectively, its inhibi-
tory activity on SERCA2a (Jackson and Colyer, 1996; Tada
and Kadoma, 1989). It has been in fact shown that phospho-
lamban, in its nonphosphorylated form, binds to SERCA2a
and inhibits this pump by lowering its affinity for Ca2,
whereas the phosphorylated form does not exert the inhibition
(Toyofuku et al., 1993). PLB is phosphorylated at two sites,
namely at Ser-16 for a cAMP-dependent phosphokinase and at
Thr-17 for a Ca2/calmodulin-dependent phosphokinase. It
was recently demonstrated that the phosphorylation at Ser-16
is a prerequisite for the phosphorylation at Thr-17 (Luo et al.,
1998). Previous studies on a shorter fragment of PLB (1–20
amino acids) indicated that the phosphorylation leads to a local
perturbation in the secondary structure (Mortishire-Smith et al.,
1995) and to a weakened interaction with SERCA (Levine et
al., 1999). Evidence was given for a specific interaction be-
tween Ser-16P and Arg-14 in a short PLB fragment (9–20
amino acids) (Quirk et al., 1996), whereas other authors, from
MD simulation data, proposed that the guanidinium groups of
both Arg-13 and Arg-14 have the potential to interact with the
phosphoryl group of Ser-16P (Mortishire-Smith et al., 1995,
1998). Recently, the structure of a 36-amino-acid-long N-
terminal fragment of PLB (PLB36) in aqueous solution con-
taining 30% trifluoroethanol (TFE) was determined by nuclear
magnetic resonance (NMR) (Pollesello et al., 1999), and PLB
was shown to assume a conformation in which two -helices
are connected by a less structured turn centered at residues
Glu-19-Pro-21 (near the PLB phosphorylation sites). In the
present study the structure of the 36-residue N-terminal frag-
ment of PLB phosphorylated at both Ser-16 and Thr-17 is
determined. The structures obtained for the phosphorylated
and unphosphorylated PLB1–36 under the same experimental
conditions are compared, and the effect of the phosphorylation
is discussed.
MATERIALS AND METHODS
Synthesis of the doubly phosphorylated
phospholamban fragment
The 36-amino acid PLB peptide phosphorylated at Ser-16 and Thr-17 and
with a mutation at the carboxy terminus (Cys-363Ser) was synthesized at
MedProbe AS (Norway). The Cys-363Ser mutation at the C terminus was
introduced to prevent dimerization, rather then using DTTd10, otherwise
required for the protection of the Cys SH group. The peptide was purified
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by reverse phase high-pressure liquid chromatography using a C-18, 5 m,
250  4.6-mm column. A linear gradient of acetonitrile and 0.075%
trifluoroacetic acid (TFA) (20%–50% in 30 min) in 0.1% TFA was used for
elution. The purified peptide was further characterized by MALDI-TOF
mass spectrometry in reflector mode with a BIFLEX mass spectrometer
using a 337-nm nitrogen laser for the ionization of the sample. The sample
was applied in a solution containing 30% acetonitrile/0.1% TFA together
with a droplet of sinapinic acid matrix for mass spectrometry analysis.
The total amount of purified peptide was 10 mg, and the purity of the
peptide was 96% according to mass spectrometry and high-pressure liquid
chromatography.
NMR spectra
1H- and 31P-NMR spectra were acquired at 600 and 242 MHz, respectively,
on a Varian UNITY600 NMR spectrometer. One-dimensional and two-
dimensional NMR spectra were obtained for a 3-mM solution of the
36-amino acids fragment of phospholamban phosphorylated on Ser-16 and
Thr-17 (C36S mutated) in the solvent mixture H2O/D2O/d3-TFE (perdeu-
terated trifluoroethanol) (63:7:30). The pH was adjusted to 3.05  0.05
(uncorrected for deuterium isotope effects) with microliter amounts of
NaOD. Correlation spectroscopy (COSY), total correlation spectroscopy
(30–90 ms), and nuclear Overhauser-effect spectroscopy (NOESY) (40–
200 ms) spectra were recorded at 17°C and 27°C by the States-time
proportional phase incrementation method (Marion et al., 1989), using a
spectral width of 8.5 ppm. The two-dimensional data were weighted and
Fourier transformed to 2 k  1 k real point matrices. The transmitter
presaturated (2.0 s) residual solvent line was reduced by deconvolution,
and NOESY data was taken with the Watergate sequence (Piotto et al.,
1992). The spectra were referenced to the residual solvent signal (4.75 ppm
at 27°C, 0.01 ppm/°C). A series of 10 one-dimensional spectra was
acquired at different temperatures from 2°C to 47°C (data not shown) to
investigate the temperature dependence of the chemical shifts of the
backbone NH protons.
Assignment of the NMR spectra
The spectra of di-P-(C36S)PLB36 (36-amino acid N-terminal fragment of
human phospholamban Cys-363Ser mutated and phosphorylated at
Ser-16 and Thr-17) display good chemical shift dispersion. The complete
spin-system and sequential assignments were obtained according to Wu¨th-
rich (1986) by use of COSY, total correlation spectroscopy, and NOESY
spectra acquired at 17°C and 27°C. Differences in the temperature depen-
dence of the amido proton chemical shifts were sufficient to unravel
resonance overlap. Stereospecific assignments for the methylene protons
were deduced from coupling constants JHH measured from the COSY
spectra and from intraresidual nuclear Overhauser enhancement (NOE)-
cross-peak intensities.
Structure generation and refinement
A series of NOESY spectra was acquired at 17°C with four different
mixing times (50, 80, 120, 170 ms). The integrated cross-peak intensities
(I) were used in a NOESY-build-up analysis. Distance restraints were
extracted from the initial slope of a second-order polynomial fitted to
integrated cross-peak volumes of the NOE-series with the initial condition
I(m 0) 0. Some of the intramethylene and sequential NOEs served for
the calibration. When a distance could not be extracted from the build-up
curve, owing to a partial (10%) overlap, a poor signal-to-noise ratio or
disturbances, it was only required that the distance was at most 6.0 Å. The
upper bounds were extended by 1.0 Å for each pseudo atom. The distances
were initially classified as short, medium, and long to provide restrains for
the generation of the first set of structures. The restraint data were supple-
mented with distance restraints derived from the 200-ms NOE-spectrum
acquired at 17°C. During the refinement the distances from the NOESY-
build-up analysis were given a 40%/10% uncertainty and from the
200-ms NOE-spectrum a 50%/20% uncertainty.
Coupling constants (J) were measured by the J-doubling method
(McIntyre and Freeman, 1992) from the fine structures of COSY
cross-peaks. Dihedral angles  and  characterized by intermediate J
values were not constrained, but small and large JNH and JHH were
related to staggered conformers (30°) on the basis of Karplus func-
tions and intraresidual NOEs. The H-H distance and dihedral angle
restraints were calculated with the software FELIX (MSI). Finally, the
data were imported in the software InsightII (MSI) to create, evaluate
and refine a family of structures, and, eventually, to back calculate
simulated NOESY spectra for comparison.
Structures were generated by distance geometry (DGII) followed by
simulated annealing (force field cvff). A set of 50 structures was
computed. The structures with least restraint violations were used to
back calculate NOE matrices. Based on the comparison of the back-
calculated and experimental NOE spectra it became possible to unam-
biguously identify a few more NOEs and impose corresponding dis-
tance restraints. Also the  dihedral angles in the -helical segments
were constrained (60°) provided that an H-chemical shift departed
from the corresponding random coil value by more than 0.2 ppm. A
new set of structures was subsequently calculated. In total there were
530 distance and 27 dihedral angle restraints excluding those that were
defined more accurately by the covalent structure alone. These redun-
dant NOE-derived restraints were consistent with the covalently im-
posed limits obtained from the sequential tetragonal bound smoothing,
which indicated that the calibration of distances was correct. The
restraint violations of the final accepted family of structures were below
0.1 Å. Finally, to consider the role of Coulombic interaction between
the phosphorous of Ser-16 and Thr-17 with Arg-9, Arg-13, and Arg-14
the final family of structures were subjected to a minimization in the
presence of charges and NMR-based restraints. The distance dependent
dielectric constant was given value of 1.4 F  m1.
RESULTS AND DISCUSSION
Preparation of the sample
Solubility tests were performed to assess which conditions
(TFE concentration, temperature, pH values) were suitable
FIGURE 1 31P-NMR spectrum acquired at 242 MHz for a sample of 3
mM di-P-(C36S)PLB36 in H2O/D2O/d3-TFE (63:7:30). The pH was ad-
justed to 3.05  0.05 (uncorrected for deuterium isotope effects). The
assignments are 0.56 ppm for phosphoserine and 0.43 ppm for phospho-
threonine. The scale (in ppm) is referenced with respect to CTP.
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for a stable aqueous NMR sample containing millimolar
concentrations of di-P-(C36S)PLB36. Among some possi-
ble solutions, it was preferential to prepare a 3-mM solution
of the 36-amino acids fragment of phosphorylated phospho-
lamban in the solvent mixture H2O/D2O/d3-TFE (63:7:30)
at pH 3.05  0.05 and to study this sample at 27°C. This
choice was also dictated by the fact those conditions were
the same at which the unphosphorylated PLB1–36 was
soluble, and it was thus possible to compare the structures
obtained for phosphorylated and unphosphorylated
PLB1–36 in the same solution. It should be pointed out that
the phosphate groups maintain one net charge at the pH
value selected for the experiment. In fact, for phosphoserine
and phosphothreonine peptides, the pKa1 of the phosphoryl
group lies below 2, whereas the pKa2 is at 5.9 (Hoffmann et
al., 1994). The presence of TFE, also needed for the solu-
bility, could be important also to mimic the transmembrane
environment of part of the peptide. A 31P-NMR spectrum
was acquired (Fig. 1) and shows two well-resolved peaks
that could be assigned to phosphoserine (0.56 ppm) and
phosphothreonine (0.43 ppm).
Assignment
The complete spin-system and sequential assignments are
listed in Table 1. More than 600 NOEs were assigned,
and all of the 34 possible intra-NH-CH correlations
were observed in the finger-print region. The secondary
shift (		) of CH (defined as the difference between the
chemical shift observed for di-P-(C36S)PLB36 in aque-
ous solution at pH 3.05 with 30% TFE and the random
TABLE 1 1H-NMR assignment of 36-amino acid fragment of phospholamban phosphorylated on Ser-16 and Thr-17 (C36 3 S
mutated) in the solvent mixture H2O/D2O/d3-TFE (63:7:30)
Amino
acid # HN HA













MET 1 4.152 2.103 2.569
GLU 2 8.760 4.534 2.232 1.962 2.477
LYS 3 8.639 4.200 1.838 1.510 1.410 1.684 2.915
VAL 4 8.183 3.921 2.077 0.970 0.887
GLN 5 8.035 4.129 2.083 2.021 2.276 7.425 6.784
TYR 6 7.882 4.360 3.088 3.002 7.036 6.762
LEU 7 8.218 4.156 1.749 1.698 1.567 0.884 0.876
THR 8 7.828 4.159 4.269 1.219
ARG 9 7.997 4.190 1.859 1.662 3.138 7.206
SER 10 8.018 4.289 3.871 3.779
ALA 11 7.945 4.255 1.421
ILE 12 7.734 4.048 1.856 1.535 1.164 0.807 0.870
ARG 13 8.031 4.401 1.859 1.755 1.679 1.609 3.182 7.381
ARG 14 8.704 4.413 2.020 1.879 1.665 3.180 7.500
ALA 15 8.492 4.178 1.439
SER 16 8.531 4.442 4.221 4.172
THR 17 7.859 4.526 4.795 1.289
ILE 18 7.757 4.056 1.861 1.186 0.813 0.905
GLU 19 8.217 4.392 2.127 2.453
MET 20 7.965 4.682 2.050 2.532
PRO 21 4.482 2.493 1.956 2.063 3.930 3.602
GLN 22 8.921 4.002 2.074 2.440 7.458 6.763
GLN 23 8.888 4.092 2.091 2.453 7.485 6.819
ALA 24 7.421 4.147 1.468
ARG 25 7.872 3.930 1.867 1.682 1.583 3.189 7.295
GLN 26 8.114 4.040 2.124 2.462 2.363 7.387 6.740
LYS 27 7.660 4.063 1.948 1.446 1.676 1.593 2.944
LEU 28 8.117 4.015 1.769 1.704 1.518 0.857 0.812
GLN 29 8.189 4.012 2.103 2.484 2.360 7.192 6.697
ASN 30 7.915 4.488 2.892 2.801 7.495 6.836
LEU 31 7.905 4.124 1.723 1.625 1.516 0.851 0.791
PHE 32 8.117 4.396 3.213 3.079 7.176 7.228
ILE 33 8.025 3.918 1.628 1.233 0.849 0.871
ASN 34 7.893 4.577 2.620 2.533 7.282 6.765
PHE 35 7.991 4.710 3.269 3.021 7.269 7.212
SER 36 7.777 4.398 3.917 3.833
The pH was adjusted to 3.05  0.05 (uncorrected for deuterium isotope effects).
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coil chemical shift for each residue) is shown in Fig. 2.
Negative (upfield) 		 values are related to -helical
secondary structure (Wishart et al., 1992). In the same
figures, for comparison, the secondary shift of CH of
the nonphosphorylated PLB36, acquired at the same con-
ditions, are shown (Pollesello et al., 1999). The region
from Arg-9 to Ile-18 appears much less structured in
di-P-(C36S)PLB36 than in the unphosphorylated peptide.
Such data are in agreement with the results of Quirk et al.
(1996) obtained for shorter PLB peptides in phosphory-
lated and unphosphorylated form. The one-dimensional
NMR spectra of 3 mM di-P-(C36S)PLB36 in 63%
H2O/7% D2O/30% d3-TFE, pH 3.05  0.05, were ac-
quired at different temperatures, namely from 0°C to
40°C in 5°C steps (data not shown). The temperature-
dependent shift of a number of the backbone NH protons
do not follow the temperature-dependent shift of the
water (10 ppb/°C), thus indicating the presence of
several H-bonds. When compared with the same spectra
acquired for the unphosphorylated PLB (Pollesello et al.,
1999) it can be noticed that the overall dispersion of the
NH peaks in the fingerprint region (9  	  7 ppm) is
similar for di-P-(C36S)PLB36 and PLB36.
FIGURE 2 The secondary shift (		) of the CH (defined as the difference between the chemical shift of the CH of each amino acid observed in the
peptides with the correspondent value observed in a random coil conformation) is plotted for every residue in sequence of di-P-(C36S)PLB36 and PLB36
in water solution at pH 3.05 with 30% TFE. Negative (upfield) 		 values are associated with -helical secondary structure and positive (downfield) 		
values with -structure (Wishart et al., 1992). The values indicate that the residues in the region from Arg-9 to Ile-18 are much less structured in the
phosphorylated peptide than in the nonphosphorylated.
TABLE 2 Characteristics of the structures
Parameters Number of NOE-restraints
Short range 299
Medium range (i  4) 229







For region 1–15 1.66  0.78 3.38  0.92
For region 1–17 2.14  0.68 3.67  0.89
For region 22–36 0.53  0.16 2.02  0.29
Data were computed from a family of 24 structures with no violations
0.1Å. Short range are restraints within the same residue; medium and
long range are restraints within residues with sequence separation 
4 and
4, respectively. On the average there were 14.4 nontrivial NOE-derived
restraints per residue.
Number of 
 and  angles in core or allowed in the Ramachandran plot:
94%.
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Structure of di-P-(C36S)PLB36
The structure of di-P-(C36S)PLB36 was determined from
530 distance and 27 dihedral restraints excluding those that
were defined more accurately by the covalent structure
alone (Table 2). Twenty-four structures of di-P-
(C36S)PLB36 deduced from NMR data with no violations
0.1 Å are shown in Fig. 3 after being superimposed on the
C of the residues 22–35. In all of the structures, both the
C-terminal fragment (from amino acids 22–35) and the N
terminus (from amino acids 2–12) are -helices. When
superimposing the 24 NMR structures on the C-terminal
helix, the N-terminal helix appears dispersed in a cone with
an opening angle of 80°. To compare the structures of the
phosphorylated and nonphoaphorylated PLB peptides was
convenient to compute the so called “packing parameters”
(defined for -helix dimers by Chothia et al. (1981) for the
two sets of structures and compare the average values of the
crossing angle  (defined as the torsion angle between the
axes of the two helices when projected on a contact plane)
and the distance of closest contact d in the two sets. Ac-
cording to the definition, for   0° the two helices are
perfectly parallel and orthogonal for   90°. When the
axes of the two helices are on the same plane, d  0. In the
case of di-P-(C36S)PLB36,   100  35° and d  7.9 
4.6 Å, when the average and standard deviation values were
calculated over 24 structures with no violations 0.1 Å.
The values of  and d for the unphosphorylated PLB36
were 80  20° and 7.0  4.0 Å, respectively, when calcu-
lated for the family of 18 structures with no violations 0.2
Å shown in our previous paper (Pollesello et al., 1999).
Therefore neither in the nonphosphorylated nor in the phos-
phorylated PLB structures the two -helices are closely
packed. However, the standard deviation of the  value
obtained for the phosphorylated peptide is larger than for
the unphosphorylated peptide, indicating even more loose
packing.
We attribute the very loose packing of the phosphorylated
peptide to the phosphorylated amino acids that disrupt the
N-terminal helix adjacent to the turn connecting to the
C-terminal helix (Fig. 2). Whereas in the nonphosphory-
lated PLB the region from Arg-13 to Thr-17 is an -helix
and only the short region from Ile-18 to Pro-21 is a less
structured turn (Pollesello et al., 1999).
It appears that the two helices are further apart from each
other in the phosphorylated peptide than in the nonphos-
phorylated form. However, structural integrity in the phos-
phorylated region may still be present due to ionic bridges
between the phosphate groups of the two phosphorylated
FIGURE 3 Structures of di-P-(C36S)PLB36 deduced from NMR data.
Twenty-four structures with no violations 0.1 Å are superimposed on the
C of the residues 22 to 35 in the C-terminal helix. The root mean square
deviation for the backbone atoms from residue 22 to 35, calculated for this
family of structures is 0.69  0.28 Å. The N-terminal helices of the 24
structures appear dispersed in a cone with an opening of 80°. The
interhelix angle is 110  40° (n  26). (A and B) Orthogonal views of the
structure family
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amino acids (Ser-16 and Thr-17) and two arginines (Arg-13
and Arg-14).
When minimizing the structures in the presence of
Coulumbic interactions, we found favorable interactions
between the side chain groups. In the majority of the
structures of the family, in fact, the distance from the
carbon CZ of Arg-13 to the phosphorus atom of Thr-17 is
between 3.85 and 5.50 Å, and the distance from the
carbon CZ of Arg-14 to the phosphorus atom of Ser-16 is
between 4.25 and 6.00 Å (Fig. 4 A). In a few structures
of the family, also Arg-25 comes close to the phosphate
group of Ser-16, whereas Arg-9 is never close to either
phosphate groups. A comparison of the structure of di-
P-(C36S)PLB36 and PLB36 is shown in Fig. 4 B, where
two representative structures are superimposed on the C
of the residues 22–35. It can be noticed that the interac-
tion between the phosphate groups and the arginine polar
heads in di-P-(C36S)PLB36 create a second bend (the
first being located on the proline residue) with the result
that the distance between the two -helices in di-P-
(C36S)PLB36 is bigger than in PLB36. The structure
shown in Fig. 4 is consistent with the structural data on
the direct effects of phosphorylation on the preferred
backbone conformation of peptides described by Tholey
et al. (1999).
A molecular model of the transmembrane domain of
phospholamban was proposed, in which a symmetric
homopentamer composed of a left-handed coiled coil of
-helices (Simmerman et al., 1996) is stabilized by a
leucine-isoleucine zipper. In a separate publication
(Pollesello et al., 1999), the structure PLB36 was re-
solved by NMR and connected to the transmembrane
pentamer model proposed previously. In this way a
model of the whole phospholamban in its pentameric
form was generated in which the inner side of the cyto-
plasmic domain of the pentamer (where the helices face
one another) was lined by polar residues (Gln-23, Gln-26,
and Asn-30), whereas the positively charged Arg-25 and
Lys-27 side chains were on the outer side.
Because the present data show that the phosphorylation
of PLB36 occurs without any modification of the structure
in the fragment 21–36, which remains as a well-character-
ized -helix, it is possible to use the same docking method
described previously and build a model of the phosphory-
lated PLB pentamer. Molecular modeling was performed to
evaluate if the interaction between the phosphate groups of
one monomer and the Arg-25 or Lys-27 of the neighbor
monomers in the pentamer is possible. The data (not shown)
did not confirm this hypothesis because in all the structures
analyzed none of the phosphate groups on the N terminus
was close to any of the positively charged groups of the C
terminus of the neighbor monomers.
Indeed, a role of the phosphorylation in the stabilization
of the PLB pentamer structure was proposed by Cornea et
al. (1997). The authors performed electron paramagnetic
resonance experiments on lipid reconstituted recombinant
PLB, showed a phosphorylation-dependent increase in the
degree of oligomerization, but concluded that this effect was
due simply to a reduced electrostatic repulsion among the
phosphorylated PLB monomers. This explanation, not
based on any specific interdomain electrostatic interaction,
is consistent with our data.
Recently, the structure of a point mutated (Cys-413Phe)
monomeric PLB was resolved by NMR in a mixture of
organic solvents (CHCl3/MeOH) (Lamberth et al., 2000).
The family of structures shown in that paper was consistent
with the data obtained for PLB36 in water/TFE (Pollesello
et al., 1999). It would be of interest to compare the structure
FIGURE 4 Structures of di-P-(C36S)PLB36 deduced from NMR data. (A) Backbone ribbons from Arg-9 to Thr-17 and the side chains of amino acids
Arg-9 (cyan), Arg-13 (magenta), Arg-14 (red), Ser-16 (yellow), and Thr-17 (gold) of the structures of di-P-(C36S)PLB36 are shown after superimposing
the backbones. The proximity of the positively charged side chain of Arg-13 with the negatively charged phosphate group of Thr-17 can be seen, as well
as the proximity of Arg-14 with Ser-16. (B) Structure of di-P-(C36S)PLB36 with the fewest NOE violation (magenta) and the structure of PLB36 with the
fewest NME violation (yellow) described elsewhere (Pollesello et al., 1999) are shown after being superimposed in their C-terminal -helices (from amino
acids 22–35). The side chains of amino acids Arg-9, Arg-13, Arg-14, Ser-16, Thr-17, and Pro-21 are shown on the backbone ribbons of the two peptides.
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of the di-phosphorylated PLB in the different two solvent
systems to understand if the structural changes induced by
the two phosphate groups are 1) independent of the envi-
ronment and 2) maintained also in the whole length PLB.
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